Phaseline

Companies › Shaanxi Micot Pharmaceutical Technology

Shaanxi Micot Pharmaceutical Technology: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Genitourinary, Other, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MT1013
Calcimimetic agent (allosteric modulator of calcium-sensing receptor)
CASRPhase 3Secondary Hyperparathyroidism, Chronic Kidney Disease; Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisNov 2026
MT200605
TrkB (NTRK2) receptor agonist
NTRK2Phase 2Acute Ischemic Stroke–
MT1011
Factor IIa and Factor Xa inhibitor reversal agent
F2, F10Phase 1Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06976177MT1013Phase 2Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on HemodialysisGenitourinaryAug 2025
NCT07024160MT1011Phase 1Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of AnticoagulationOtherApr 2026
NCT07205328MT200605Phase 2Acute Ischemic StrokeNeurologyJun 2026
NCT07122401MT1013Phase 3Secondary Hyperparathyroidism, Chronic Kidney DiseaseGenitourinaryNov 2026

Targets

CASR (1) F2 (1) F10 (1) NTRK2 (1)

Companies with the same targets

Bayer Roche Amgen Calcilytix Therapeutics, Inc., a BridgeBio company CSL Behring Takeda VarmX Xuanzhu Biopharmaceutical Dompé Farmaceutici Nuvation Bio

Companies built like this

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) H. Lundbeck Shanghai Bao Pharmaceuticals Akebia Therapeutics Leadiant Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.